Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma
- PMID: 17308088
- DOI: 10.1158/0008-5472.CAN-06-3311
Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma
Abstract
The majority of human melanomas harbor activating mutations of either N-RAS or its downstream effector B-RAF, which cause activation of mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase and the ERK MAPK cascade. The melanoma-relevant effectors of ERK activation, however, are largely unknown. In this work, we show that increased ERK activation correlates strongly with mutational status of N-RAS or B-RAF in 21 melanoma cell lines. Melanoma lines that were wild-type for RAS/RAF showed low levels of ERK activation comparable with primary human melanocytes. Through supervised analysis of RNA expression profiles, we identified 82 genes, including TWIST1, HIF1alpha, and IL-8, which correlated with ERK activation across the panel of cell lines and which decreased with pharmacologic inhibition of ERK activity, suggesting that they are ERK transcriptional targets in melanoma. Additionally, lines lacking mutations of N-RAS and B-RAF were molecularly distinct and characterized by p53 inactivation, reduced ERK activity, and increased expression of epithelial markers. Analysis of primary human melanomas by tissue microarray confirmed a high correlation among expression of these epithelial markers in a heterogeneous sample of 570 primary human tumors, suggesting that a significant frequency of primary melanomas is of this "epithelial-like" subtype. These results show a molecularly distinct melanoma subtype that does not require ERK activation or epithelial-mesenchymal transformation for progression.
Similar articles
-
The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.Matrix Biol. 2015 Oct;48:66-77. doi: 10.1016/j.matbio.2015.05.007. Epub 2015 May 16. Matrix Biol. 2015. PMID: 25989506 Free PMC article.
-
SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant.Cancer Res. 2004 Aug 15;64(16):5556-9. doi: 10.1158/0008-5472.CAN-04-1669. Cancer Res. 2004. PMID: 15313890
-
Mutation of B-Raf in human choroidal melanoma cells mediates cell proliferation and transformation through the MEK/ERK pathway.J Biol Chem. 2003 Oct 24;278(43):42409-18. doi: 10.1074/jbc.M308709200. Epub 2003 Aug 12. J Biol Chem. 2003. PMID: 12917419
-
MEK and RAF inhibitors for BRAF-mutated cancers.Expert Rev Mol Med. 2012 Oct 12;14:e17. doi: 10.1017/erm.2012.11. Expert Rev Mol Med. 2012. PMID: 23058743 Review.
-
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.Leukemia. 2011 Jul;25(7):1080-94. doi: 10.1038/leu.2011.66. Epub 2011 Apr 15. Leukemia. 2011. PMID: 21494257 Review.
Cited by
-
Identification of a novel MTOR activator and discovery of a competing endogenous RNA regulating autophagy in vascular endothelial cells.Autophagy. 2014 Jun;10(6):957-71. doi: 10.4161/auto.28363. Autophagy. 2014. PMID: 24879147 Free PMC article.
-
Pharmacologically enhanced expression of GPNMB increases the sensitivity of melanoma cells to the CR011-vcMMAE antibody-drug conjugate.Mol Oncol. 2008 Jun;2(1):81-93. doi: 10.1016/j.molonc.2008.02.002. Epub 2008 Feb 16. Mol Oncol. 2008. PMID: 19383330 Free PMC article.
-
Application of angiogenesis to clinical dermatology.Adv Dermatol. 2008;24:89-103. doi: 10.1016/j.yadr.2008.09.010. Adv Dermatol. 2008. PMID: 19256307 Free PMC article. Review. No abstract available.
-
Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?Nat Rev Cancer. 2010 Dec;10(12):842-57. doi: 10.1038/nrc2960. Epub 2010 Nov 24. Nat Rev Cancer. 2010. PMID: 21102635 Free PMC article. Review.
-
Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function.Front Immunol. 2013 Oct 28;4:346. doi: 10.3389/fimmu.2013.00346. Front Immunol. 2013. PMID: 24194739 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous